ICHM

There is a critical need for new therapies for T-cell lymphomas, and with ongoing trials of mTOR and aurora kinase inhibitors, PI3K inhibitors, and others, new options may be on the horizon.

In this interview we discuss the latest therapy developments in the treatment of multiple myeloma.

A handful of novel antibody-based therapies may soon emerge for the treatment of acute myeloid leukemia, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies.